Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: The data of the meta-analyses

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Chiurchiu, Carlos ^a   Remuzzi, Giuseppe ^a   Ruggenenti, Piero ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; SYSTEMATIC REVIEW; URINARY EXCRETION; ANIMAL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; HYPERTENSION; KIDNEY FUNCTION TEST; MALE; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIET, PROTEIN-RESTRICTED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; PROTEINURIA; RAMIPRIL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20844461643     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110968     Document Type: Conference Paper

References (58)

1. Lysaght MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13: S37-S40, 2002
2. Schieppati A, Perico N, Remuzzi G: Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Nephrol Dial Transplant 18: 858-859, 2003
3. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12: 2753-2758, 2001
4. Schieppati A, Remuzzi G: Fighting renal diseases in poor countries: Building a global fund with the help of the pharmaceutical industry. J Am Soc Nephrol 15: 704-707, 2004
5. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307: 652-659, 1982
6. Campbell RC, Ruggenenti P, Remuzzi G: Halting the progression of chronic nephropathy. J Am Soc Nephrol 13[Suppl 3]: S190-S195, 2002
7. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 16 136: 604-615, 2002
8. Pisoni R, Ruggenenti P, Remuzzi G: Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 61: 733-745, 2001
9. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
10. Abbate M, Benigni A, Bertani T, Remuzzi G: Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 14: 304-312, 1999
11. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G: Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30: 488-496, 1986
12. Bertani T, Zoja C, Abbate M, Rossini M, Remuzzi G: Age-related nephropathy and proteinuria in rats with intact kidney exposed to diets with different protein options. Lab Invest 60: 196-204, 1989
13. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G: Transforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am J Pathol 161: 2179-2199, 2002
14. Rossing P, Hommel E, Smidt UM, Parving H-H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42: 715-719, 1993
15. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G, on behalf of the "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN): Urinary protein excretion rate is the best independent predictor to ESRF in non-diabetic chronic nephropathies. Kidney Int 57: 1209-1216, 1998
16. Tarver-Carr ME, Brancati FL, Eberhardt MS, Powe NR3A Proteinuria and the risk of chronic kidney disease (CKD) in the United States [Abstract]. J Am Soc Nephrol 11: 168A, 2000
17. Hoy WE, Wang Z, VanBuynder P, Baker PR, Mathews JD: , The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 60: 243-248, 2001
18. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
19. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
20. Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003
21. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986
22. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
23. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36: 383-388, 1976
24. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118: 129-138, 1993
25. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
26. Ruggenenti P, Perna A, Lesti M, Pisoni R, Mosconi L, Arnoldi F, Ciocca I, Gaspari F, Remuzzi G: Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group. Kidney Int 58: 2093-3101, 2000
27. Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31: 752-759, 1987
28. Mitch W, Remuzzi G: Diets for patients with chronic kidney disease, still worth prescribing. J Am Soc Nephrol 15: 234-237, 2004
29. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 337: 1299-1304, 1991
30. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42: 452-458, 1992
31. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hyper tens 5: 423-430, 1992
32. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63: 58-62, 1997
33. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM, et al.: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309: 833-837, 1994
34. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111: 184-192, 1995
35. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
36. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
37. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
38. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10: 997-1006, 1999
39. Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia: ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12: 2832-2837, 2001
40. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001
41. Schrier RW, Estacio RO: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A pooled analysis of individual-patient data from 11 randomized, controlled trials. Ann Intern Med 135: 138-139, 2001
42. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155: 1073-1080, 1995
43. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 35: 695-707, 2000
44. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
45. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995
46. Giatras I, Lau J, Levey AS: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 127: 337-345, 1997
47. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-converting enzyme inhibition and progression of renal disease: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140, 2001
48. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001
49. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
50. Jafar TH, Schmid CH, Stark PC, Landa M, de Jong PE, de Zeeuw D, Maschio G, Toto R, Levy AS: The optimal level 7 of blood pressure and urine protein excretion for the prevention of progression of chronic renal insufficiency [Abstract]. J Am Soc Nephrol 11: A0345, 2000
51. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124: 627-632, 1996
52. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31: 954-961,1998
53. Silbiger S, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 25: 515-533, 1995
54. Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: A meta-analysis. J Am Soc Nephrol 11: 319-329, 2000
55. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS: The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis. Nephrol Dial Transplant 18: 2047-2053, 2003
56. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN). J Am Soc Nephrol 11: 88-96, 2000
57. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
58. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160: 685-693, 2000